* If you want to update the article please login/register
On Day 1, participants will be given a single dose of probe substrate drug. On Days 11 to 20, participants will then receive GSK3640254 200 mg per day for the first time daily, followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.
Source link: https://clinicaltrials.gov/ct2/show/NCT04425902
Single doses of caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole were included in Arm 1's investigations. The Arm 3 probe is pioglitazone, according to pioglitazone. The probes will be launched on Day -1, followed by the first dose of enasidenib on Day 1 in Part 1. On Day 28, the probes will be administered for the second time. The subject will begin a second round of daily enasidenib doses on the next day, while Part 2 of the trial begins the next day.
Source link: https://clinicaltrials.gov/ct2/show/NCT03720366
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions